BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Established in 2005 by pharma veteran Dr. Satyanarayana Chava, Laurus Labs Ltd. is a vertical integrated pharma company operating across three segments – active pharmaceutical ingredients, formulations and Synthesis CDMO (contract development and manufacturing organization).
From an anti-AIDS API supplier, the company has been rigorously diversifying its product basket by moving into niche APIs and formulations.
Laurus Labs is well poised to benefit in the post-pandemic scenario with an integrated business model and focused approach.
We like the company as it continues to target products where it has a competitive edge and an ability to manage supply chain better, with improved financials.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR